COVID‐19 and non‐alcoholic fatty liver disease: Two intersecting pandemics
European Journal of Clinical Investigation2020Vol. 50(10), pp. e13338–e13338
Citations Over TimeTop 1% of 2020 papers
Abstract
NAFLD can play a role in the outcome of COVID-19 illness due to frequent association with comorbidities. Initial evidences suggest that increased liver fibrosis in NAFLD might affect COVID-19 outcome. In addition, long-term monitoring of post-COVID-19 NAFLD patients is advisable, to document further deterioration of liver damage. Further studies are required in this field.
Related Papers
- → The metabolic syndrome: Insulin resistance(2009)79 cited
- → Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis(2021)24 cited
- → Prevalence of fatty liver in metabolic syndrome(2020)16 cited
- → Nash As Part of the Metabolic (Insulin Resistance) Syndrome(2004)8 cited
- → Study of insulin status in metabolic syndrome in correlation with presence of other risk factors(2016)